Among 2 analysts covering Aspen Technology (NASDAQ:AZPN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aspen Technology had 4 analyst reports since November 28, 2018 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Wednesday, November 28. Benchmark maintained it with “Buy” rating and $113 target in Thursday, March 14 report. The rating was upgraded by Benchmark to “Buy” on Friday, January 4. See Aspen Technology, Inc. (NASDAQ:AZPN) latest ratings:
22/03/2019 Broker: BidaskScore Rating: Buy Upgrade
14/03/2019 Broker: Benchmark Rating: Buy New Target: $113 Maintain
04/01/2019 Broker: Benchmark Old Rating: Hold New Rating: Buy Upgrade
28/11/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Buy New Target: $100 Upgrade
The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 7.79% or $3.03 during the last trading session, reaching $41.91. About 310,856 shares traded or 128.81% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 7, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04The move comes after 8 months positive chart setup for the $1.09 billion company. It was reported on Apr, 7 by Barchart.com. We have $43.17 PT which if reached, will make NASDAQ:IFRX worth $32.64M more.
More notable recent Aspen Technology, Inc. (NASDAQ:AZPN) news were published by: Businesswire.com which released: “Aspen Technology to Present at the Berenberg Design Software Conference USA 2019 – Business Wire” on March 08, 2019, also Nasdaq.com with their article: “Aspen Technology (AZPN) Beats on Q2 Earnings, Ups ’19 View – Nasdaq” published on January 24, 2019, Nasdaq.com published: “Bull of the Day: Aspen Technologies (AZPN) – Nasdaq” on September 28, 2018. More interesting news about Aspen Technology, Inc. (NASDAQ:AZPN) were released by: Nasdaq.com and their article: “Aspen Technology (AZPN) Q2 Earnings: What’s in the Cards? – Nasdaq” published on January 18, 2019 as well as Seekingalpha.com‘s news article titled: “Aspen Technology Building Up Portfolio – Seeking Alpha” with publication date: August 23, 2018.
The stock increased 0.24% or $0.25 during the last trading session, reaching $104.84. About 335,725 shares traded. Aspen Technology, Inc. (NASDAQ:AZPN) has risen 30.16% since April 7, 2018 and is uptrending. It has outperformed by 25.79% the S&P500. Some Historical AZPN News: 04/04/2018 – Aspen to Announce First Quarter 2018 Earnings on May 2, 2018; 25/04/2018 – ASPEN TECH 3Q ADJ EPS 58C, EST. 52C; 18/04/2018 – TrendMiner Customer CP Kelco to Present Gained Operational Value of Data Analytics at OSlsoft Pl World 2018; 09/05/2018 – Aspen Tech Presenting at JPMorgan Conference May 15; 25/04/2018 – Aspen Technology 3Q Rev $125.9M; 25/04/2018 – Aspen Technology 3Q Net $37.8M; 25/04/2018 – ASPEN TECH 3Q REV. $125.9M, EST. $122.0M; 25/04/2018 – ASPEN TECH 3Q SUBSCRIPTION & SOFTWARE REV. $118.1M; 08/05/2018 – AspenTech Joins SAP® PartnerEdge® Program; Announces Availability of Aspen Mtell® on SAP App Center; 14/05/2018 – Aspen Tech Presenting at JPMorgan Conference Tomorrow
Aspen Technology, Inc., together with its subsidiaries, provides software and services in the United States, Europe, and internationally. The company has market cap of $7.30 billion. It operates through two divisions, Subscription and Software, and Services. It has a 102.28 P/E ratio. It supplies asset optimization solutions that optimize asset design, operations, and maintenance lifecycle in various industrial environments.
Investors sentiment decreased to 0.79 in 2018 Q4. Its down 0.08, from 0.87 in 2018Q3. It dropped, as 42 investors sold Aspen Technology, Inc. shares while 103 reduced holdings. 34 funds opened positions while 80 raised stakes. 64.13 million shares or 1.57% less from 65.16 million shares in 2018Q3 were reported. Moreover, Nicholas Invest L P has 0.73% invested in Aspen Technology, Inc. (NASDAQ:AZPN). Natl Bank Of America De reported 114,702 shares stake. Huntington Fincl Bank owns 1 shares for 0% of their portfolio. Caprock invested in 2,458 shares or 0.05% of the stock. Moreover, Guggenheim Capital Ltd Company has 0% invested in Aspen Technology, Inc. (NASDAQ:AZPN). Moreover, Artemis Investment Mngmt Limited Liability Partnership has 0.06% invested in Aspen Technology, Inc. (NASDAQ:AZPN) for 56,451 shares. Jacobs Levy Equity accumulated 456,184 shares. Fort Washington Investment Oh holds 0.21% or 205,623 shares. Great West Life Assurance Can reported 0% in Aspen Technology, Inc. (NASDAQ:AZPN). Invesco Limited holds 0.03% or 1.08M shares. Winslow Evans & Crocker holds 0.01% of its portfolio in Aspen Technology, Inc. (NASDAQ:AZPN) for 304 shares. Numerixs Inv Tech holds 0.04% or 1,400 shares. Stephens Ar holds 7,524 shares or 0.02% of its portfolio. Sg Americas Secs Llc invested 0% in Aspen Technology, Inc. (NASDAQ:AZPN). Merian Global Invsts (Uk) has invested 0.68% in Aspen Technology, Inc. (NASDAQ:AZPN).
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.09 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Seekingalpha.com which released: “InflaRx down 14% – Seeking Alpha” on November 19, 2018, also Globenewswire.com with their article: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” published on January 03, 2019, Globenewswire.com published: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” published on February 06, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – GlobeNewswire” with publication date: December 19, 2018.